APAF1 and neoplasm: Small molecule inhibitors targeting the DNA-binding interface of Apaf-1 may be used in new cancer therapy by combining them with other drugs, such as BH3-mimetics, to switch tumor cell fates from persistent inflammation to apoptotic cell death.